menu
    • menu

    Company profile for Viridian Therapeutics

    NEW Drugs in Dev: 5
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Viridian Therapeutics is advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s patient-centric model of innovation leverages proven biology and technology to efficiently allocate research and development resources while addressing strategic gaps related to access, delivery, quality of life, and efficacy in therapeutic areas of focus. Viridian’s most advanc...
    Viridian Therapeutics is advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s patient-centric model of innovation leverages proven biology and technology to efficiently allocate research and development resources while addressing strategic gaps related to access, delivery, quality of life, and efficacy in therapeutic areas of focus. Viridian’s most advanced program, VRDN-001, is an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody in development for thyroid eye disease (TED).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Viridian TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    221 Crescent Street Suite 401 Waltham, MA 02453
    Telephone
    Telephone
    617-272-4600
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.viridiantherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/viridiantx/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/ViridianThera

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    RDD

    RDD

    Not Confirmed

    envelop Contact Supplier

    RDD

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Viridian Price 350M Concurrent Convertible Notes & Stock Offering
    Viridian Price 350M Concurrent Convertible Notes & Stock Offering

    07 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-07/viridian-therapeutics-announces-pricing-of-upsized-concurrent-public-offerings-of-175-convertible

    PHARMIWEB
    07 May 2026
    Share Share
    Viridian Eye Disease Drug Surpasses Expectations in late-stage
    Viridian Eye Disease Drug Surpasses Expectations in late-stage

    06 May 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/viridian-eye-disease-drug-benefits-chronic-patients-late-stage-trial-2026-05-05/

    REUTERS
    06 May 2026
    Share Share
    Viridian Therapeutics: Q1 2026 Results & Key Advances
    Viridian Therapeutics: Q1 2026 Results & Key Advances

    05 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-05/viridian-therapeutics-reports-first-quarter-2026-financial-results-and-highlights-recent-progress

    PHARMIWEB
    05 May 2026
    Share Share
    Viridian's Tepezza Rival Scores Ph. 3 Win, But Investors Unsure
    Viridian's Tepezza Rival Scores Ph. 3 Win, But Investors Unsure

    31 Mar 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/viridians-other-rival-amgens-tepezza-scores-phase-3-win-investors-need-convincing

    FIERCE BIOTECH
    31 Mar 2026
    Share Share
    Viridian Elegrobart Ph3 REVEAL-1 Shows Positive TED Topline Data
    Viridian Elegrobart Ph3 REVEAL-1 Shows Positive TED Topline Data

    30 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260330779172/en/Viridian-Therapeutics-Announces-Positive-Topline-Results-from-Elegrobart-Phase-3-REVEAL1-Clinical-Trial-in-Active-Thyroid-Eye-Disease

    BUSINESSWIRE
    30 Mar 2026
    Share Share
    Viridian Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
    Viridian Announces Inducement Grants Under Nasdaq LR 5635(c)(4)

    08 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260108064915/en/Viridian-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

    BUSINESSWIRE
    08 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search